Literature DB >> 12407646

Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation.

David Tovbin1, Dalia Mazor, Marina Vorobiov, Cidio Chaimovitz, Naomi Meyerstein.   

Abstract

BACKGROUND: Oxidative stress and inflammation contribute to the high prevalence and severity of atherosclerosis, infections, and beta2-microglobulin amyloidosis; and thus, to reduced survival rate and quality of life in hemodialysis (HD) patients. Inflammation induces oxidative stress by production of the oxidants: superoxide anion, hydrogen peroxide, and hypochlorite. Intravenous iron (IVIR), administered in HD patients to correct anemia, can release free iron, that may react with hydrogen peroxide to produce the strong oxidant hydroxyl radical. Inflammation-induced lipid and protein oxidation and IVIR-induced lipid oxidation were shown in HD patients. However, IVIR-induced protein oxidation and a relationship between inflammation and IVIR-induced oxidative stress have not been reported to date.
METHODS: We examined the effect of IVIR administration on markers of protein oxidation in HD patients (advanced oxidation protein products [AOPPs], thiol, and dityrosine) in relation to such inflammatory markers as C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-alpha). Iron saccharate, 100 mg, was administered to 19 HD patients for 1 hour after 3.5 hours of high-flux dialysis. Blood samples were drawn pre-HD, pre-IVIR, and post-IVIR for iron, transferrin, TNF-alpha, AOPP, thiol, total antioxidant capacity (TEAC), and dityrosine levels and pre-HD for ferritin and CRP levels.
RESULTS: IVIR administration induced a 37% increase in AOPP level (P < 0.001), which correlated positively with pre-HD CRP level (r = 0.72; P < 0.05) and was greater in patients with a greater pre-HD TNF-alpha level (P < 0.05). IVIR administration did not affect TEAC, thiol, dityrosine, or TNF-alpha levels.
CONCLUSION: IVIR administration induced an increase in protein oxidation (AOPP levels) that was related to the degree of inflammation. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12407646     DOI: 10.1053/ajkd.2002.36334

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  20 in total

1.  Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes.

Authors:  Hirohito Ichii; Yuichi Masuda; Tania Hassanzadeh; Mateen Saffarian; Sastry Gollapudi; Nosratola D Vaziri
Journal:  Am J Nephrol       Date:  2012-06-19       Impact factor: 3.754

2.  Prolonged pain to hospital time is associated with increased plasma advanced oxidation protein products and poor prognosis in patients with percutaneous coronary intervention for ST-elevation myocardial infarction.

Authors:  Yi Feng; Chengxing Shen; Genshan Ma; Jihui Wang; Zhong Chen; Qiming Dai; Hong Zhi; Chengjian Yang; Qiang Fu; Gensheng Shang; Yuanyuan Guan
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

Review 3.  The Labile Side of Iron Supplementation in CKD.

Authors:  Itzchak Slotki; Zvi Ioav Cabantchik
Journal:  J Am Soc Nephrol       Date:  2015-05-21       Impact factor: 10.121

Review 4.  Safety of intravenous iron formulations: facts and folklore.

Authors:  Michael Auerbach; Iain C Macdougall
Journal:  Blood Transfus       Date:  2014-07       Impact factor: 3.443

Review 5.  Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD.

Authors:  Peter Van Buren; Ruben L Velez; Nosratola D Vaziri; Xin J Zhou
Journal:  Int Urol Nephrol       Date:  2011-07-10       Impact factor: 2.370

6.  Intravenous Iron Replacement Therapy Improves Cardiovascular Outcomes in Hemodialysis Patients.

Authors:  Matteo Righini; Vittorio Dalmastri; Irene Capelli; Claudio Orsi; Gabriele Donati; Maria Giovanna Pallotti; Chiara Pedone; Gianni Casella; Pasquale Chieco; Gaetano LA Manna
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

7.  An alternative pathway through the Fenton reaction for the formation of advanced oxidation protein products, a new class of inflammatory mediators.

Authors:  Guilherme Vargas Bochi; Vanessa Dorneles Torbitz; Lara Peruzzolo Cargnin; José Antonio Mainardi de Carvalho; Patrícia Gomes; Rafael Noal Moresco
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

8.  Erythropoietin-induced proliferation of gastric mucosal cells.

Authors:  Kazuro Itoh; Yoshio Sawasaki; Kyoko Takeuchi; Shingo Kato; Nobuhiro Imai; Yoichiro Kato; Noriyuki Shibata; Makio Kobayashi; Yoshiyuki Moriguchi; Masato Higuchi; Fumio Ishihata; Yushi Sudoh; Soichiro Miura
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

Review 9.  Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients.

Authors:  Francesco Locatelli; Sandro Mazzaferro; Jerry Yee
Journal:  Clin J Am Soc Nephrol       Date:  2016-05-16       Impact factor: 8.237

10.  Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients.

Authors:  Ko-Lin Kuo; Szu-Chun Hung; Yau-Huei Wei; Der-Cherng Tarng
Journal:  J Am Soc Nephrol       Date:  2008-05-21       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.